Literature DB >> 28559399

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Sanket S Dhruva1, Chenxi Huang1, Erica S Spatz1, Andreas C Coppi1, Frederick Warner1, Shu-Xia Li1, Haiqun Lin1, Xiao Xu1, Curt D Furberg1, Barry R Davis1, Sara L Pressel1, Ronald R Coifman1, Harlan M Krumholz2.   

Abstract

Randomized trials of hypertension have seldom examined heterogeneity in response to treatments over time and the implications for cardiovascular outcomes. Understanding this heterogeneity, however, is a necessary step toward personalizing antihypertensive therapy. We applied trajectory-based modeling to data on 39 763 study participants of the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to identify distinct patterns of systolic blood pressure (SBP) response to randomized medications during the first 6 months of the trial. Two trajectory patterns were identified: immediate responders (85.5%), on average, had a decreasing SBP, whereas nonimmediate responders (14.5%), on average, had an initially increasing SBP followed by a decrease. Compared with those randomized to chlorthalidone, participants randomized to amlodipine (odds ratio, 1.20; 95% confidence interval [CI], 1.10-1.31), lisinopril (odds ratio, 1.88; 95% CI, 1.73-2.03), and doxazosin (odds ratio, 1.65; 95% CI, 1.52-1.78) had higher adjusted odds ratios associated with being a nonimmediate responder (versus immediate responder). After multivariable adjustment, nonimmediate responders had a higher hazard ratio of stroke (hazard ratio, 1.49; 95% CI, 1.21-1.84), combined cardiovascular disease (hazard ratio, 1.21; 95% CI, 1.11-1.31), and heart failure (hazard ratio, 1.48; 95% CI, 1.24-1.78) during follow-up between 6 months and 2 years. The SBP response trajectories provided superior discrimination for predicting downstream adverse cardiovascular events than classification based on difference in SBP between the first 2 measurements, SBP at 6 months, and average SBP during the first 6 months. Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  antihypertensive agents; blood pressure; cardiovascular diseases; hypertension; precision medicine

Mesh:

Substances:

Year:  2017        PMID: 28559399     DOI: 10.1161/HYPERTENSIONAHA.117.09221

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

1.  N-of-1 Trials in Hypertension Are Feasible, but Are They Worthwhile?

Authors:  Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-06       Impact factor: 5.128

2.  Modulation of α-adrenoceptor signalling protects photoreceptors after retinal detachment by inhibiting oxidative stress and inflammation.

Authors:  Tong Li; Shiqi Yang; Xiangjun She; Quan Yan; Pengfei Zhang; Hong Zhu; Fenghua Wang; Xueting Luo; Xiaodong Sun
Journal:  Br J Pharmacol       Date:  2019-01-30       Impact factor: 8.739

3.  A Computational Method for Learning Disease Trajectories From Partially Observable EHR Data.

Authors:  Wonsuk Oh; Michael S Steinbach; M Regina Castro; Kevin A Peterson; Vipin Kumar; Pedro J Caraballo; Gyorgy J Simon
Journal:  IEEE J Biomed Health Inform       Date:  2021-07-27       Impact factor: 7.021

4.  Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.

Authors:  Chenxi Huang; Sanket S Dhruva; Andreas C Coppi; Frederick Warner; Shu-Xia Li; Haiqun Lin; Khurram Nasir; Harlan M Krumholz
Journal:  J Am Heart Assoc       Date:  2017-11-13       Impact factor: 5.501

5.  The association between trajectories of risk factors and risk of cardiovascular disease or mortality among patients with diabetes or hypertension: A systematic review.

Authors:  Yuan Wang; Eric Yuk Fai Wan; Ivy Lynn Mak; Margaret Kay Ho; Weng Yee Chin; Esther Yee Tak Yu; Cindy Lo Kuen Lam
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

6.  A Novel Hypertension Management Algorithm Guided by Hemodynamic Data.

Authors:  Barbara Greco; Yossi Chait; Brian H Nathanson; Michael J Germain
Journal:  Kidney Int Rep       Date:  2021-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.